Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study

Abstract

Performance of ¹⁸F-DCFPyL-PET/CT achieved the study's primary endpoint, demonstrating disease localization in the setting of negative standard imaging and providing clinically meaningful and actionable information. These data further support the utility of ¹⁸F-DCFPyL-PET/CT to localize disease in men with recurrent prostate cancer.<i>See related commentary by True and Chen, p. 3512</i>.